MarketPulse

AAV-based programs

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Opus Genetics Secures $155M Non-Dilutive Funding to Accelerate Retinal Gene Therapy Pipeline

Opus Genetics secures $155M non-dilutive funding from Oberland Capital, extending cash runway through 2029 and accelerating gene therapy development for inherited retinal diseases.
IRDclinical developmentgene therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Opus Genetics Earns Fast Company Innovation Recognition for Gene Therapy Pipeline

Clinical-stage biotech Opus Genetics named to Fast Company's 2026 most innovative companies list for gene therapy work in inherited retinal diseases.
IRDgene therapybiopharmaceutical